Andrew Oxtoby bought AIMT once, on Mar 13, 2020

Andrew Oxtoby is a person and a pharmaceutical and biotechnology executive with more than two decades of experience in the industry.( He most recently served as Chief Commercial Officer of Aimmune Therapeutics, where he built the company’s commercial organization in the United States and Europe and helped launch Palforzia, the first approved treatment for peanut allergy; he later became Aimmune’s President and CEO after Nestlé Health Science acquired the company.(

Oxtoby previously spent 16 years at Eli Lilly and Company, where he led Lilly’s U.S. insulin business as Vice President of U.S. Diabetes Connected Care and Insulins, and earlier held leadership roles in U.S. diabetes sales, international oncology, and the Netherlands operation.( He holds an M.B.A. from Harvard Business School and a Bachelor of Science in Mechanical Engineering from Purdue University.(

Written by Perplexity from public sources.